PA
ATRA icon

Parallel Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Parallel Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25
Closed -$1.82K – 3365
2023
Q1 		$1.82K Sell
25
-17
-40% -$1.65K ﹤0.01% 2803
2022
Q4 		$3.43K Buy
42
+38
+950% +$3.96K ﹤0.01% 2480
2022
Q3 		$0 Buy
+4
New +$449 ﹤0.01% 3131
2022
Q2 		– Sell
-8
Closed -$2K – 2984
2022
Q1 		$2K Sell
8
-5
-38% -$1.59K ﹤0.01% 2545
2021
Q4 		$5K Buy
13
+5
+63% +$2.1K ﹤0.01% 2371
2021
Q3 		$4K Hold
8
– – ﹤0.01% 2428
2021
Q2 		$3K Hold
8
– – ﹤0.01% 2429
2021
Q1 		$3K Hold
8
– – ﹤0.01% 2330
2020
Q4 		$4K Hold
8
– – ﹤0.01% 2074
2020
Q3 		$3K Hold
8
– – ﹤0.01% 2169
2020
Q2 		$3K Buy
+8
New +$2.02K ﹤0.01% 2065
2020
Q1 		– Sell
-2
Closed -$1K – 2385
2019
Q4 		$1K Buy
+2
New +$690 ﹤0.01% 2284

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's ATRA Position: Q2 2023 in Review

Parallel Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 25 shares — an estimated $1.82K sold.

Parallel Advisors first reported a position in ATRA in Q4 2019 and held it in 12 quarters. The position peaked at $5K in Q4 2021. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Parallel Advisors reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Parallel Advisors sold 25 Atara Biotherapeutics shares in Q2 2023, an estimated $1.82K.
  • Parallel Advisors first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 12 quarters.
  • Parallel Advisors's Atara Biotherapeutics position peaked at $5K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.